Translational Geroscience Network
转化老年科学网络
基本信息
- 批准号:10539281
- 负责人:
- 金额:$ 78.43万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-02-01 至 2024-05-31
- 项目状态:已结题
- 来源:
- 关键词:AccelerationAgingAlzheimer&aposs DiseaseAncillary StudyAnimal ModelApoptosisAutophagocytosisBasic ScienceBiological AgingBiological AssayBiologyBiology of AgingBiopsyBloodBody FluidsCardiovascular DiseasesCell AgingCellsChronicChronic DiseaseClinicalClinical DataClinical ResearchClinical TrialsCommunitiesDataDementiaDevelopmentDiabetes MellitusDiseaseDrug TargetingElderlyEpidemiologyEpigenetic ProcessFRAP1 geneFundingFutureGene ExpressionGeriatricsGeroscienceGoalsGrantHealth Care CostsHealth PolicyHealthcare SystemsHeart DiseasesHumanImmune responseInflammationInfluenza vaccinationInfrastructureInstitutionInterventionLaboratoriesLearningLifeLongevityMalignant NeoplasmsMammalsManualsMeasuresMetforminMethodsMitochondriaMorbidity - disease rateMulti-Institutional Clinical TrialMulticenter TrialsPatientsPharmaceutical PreparationsPhasePreclinical TestingProceduresProcessProtocols documentationPublishingR24ReportingResearchResearch DesignResearch PersonnelResourcesRisk FactorsSample SizeSamplingSeriesSpecimenSubgroupSystemTestingTimeTranslatingTranslationsUnited States National Institutes of Healthage relatedbiobankcell mediated immune responseclinical careclinical practicedata managementdesigndisabilitydrug repurposingearly phase trialexperiencefrailtyglycationhealthspanidiopathic pulmonary fibrosisinnovationmortalitynovelnovel strategiesolder womenpre-clinicalpreventproteostasisrecruitrepositorysample collectionsenescencesupport networktargeted agenttherapy designworking group
项目摘要
Aging is the leading risk factor for the disorders that account for the bulk of the nation's morbidity, mortality, and
health costs. Recent findings suggest it is feasible to alleviate such disorders as a group by targeting
fundamental aging processes. Several such interventions are near the point of entering human proof-of-concept
clinical trials. Since interventions that increase lifespan and healthspan in mammals now exist, we
hypothesize that clinical interventions targeting fundamental mechanisms of aging may delay, prevent,
or treat age-related diseases and disabilities as a group, instead of one at a time. To accelerate testing this
hypothesis, we propose a Translational Geroscience Network (TGN). Planning began 4 years ago through an
NIA R24 grant involving 122 investigators in the biology of aging and clinical geriatrics. Our goal is to mature this
network into a national resource starting with a subgroup of centers committed to working together using
common measures and protocols allowing network-wide learning from complementary, small-scale, proof-of-
concept “use case” clinical studies. Aim 1 is to establish a TGN to develop, implement, test, and harmonize
methods and standard operating protocols (SOPs) for translational early phase trials of agents that
target fundamental aging processes. The TGN will support development, coordination, and infrastructure
around independently-funded “use case” trials (2-3 per year) using re-purposed drugs for which preclinical or
clinical data already exist, such as a multicenter trial of senolytics for idiopathic pulmonary fibrosis, a trial of a
different drug to reduce senescent cell burden and alleviate frailty in older women, and a trial of metformin to
enhance immune responses to influenza vaccination. Based on these “use case” trials, we will streamline and
harmonize approvals, recruitment, sample collection, SOPs, and analytic procedures across the TGN. Aim 2 is
to select, optimize, and validate ancillary measures of fundamental aging processes to be assayed across
all trials to establish reference analytical capabilities. An existing cell senescence assay facility will be expanded
to analyze blood, other body fluids, cells, and biopsies from trials across and beyond the TGN to serve as a
national resource. New assays will be developed and optimized. The facility will expand to include laboratories
beyond the TGN and incorporate assays of key basic aging mechanisms, including mTOR activity, proteostasis,
autophagy, mitochondrial function, and epigenetics. Aim 3 is to provide statistical and data management
support to select efficient study designs, provide sample size estimates and support a TGN-wide data entry
platform to facilitate cross-study comparisons. Aim 4 is to develop a biobanking and repository network for
samples from the clinical trials to permit future analyses as new ancillary research questions are developed
and assays become available. A system for disseminating samples to the basic biology of aging community,
biobanking protocols, and operating manuals will be developed. Translating agents targeting basic aging
processes into interventions for the major chronic diseases and age-related disabilities could be transformative.
老龄化是疾病的主要危险因素,占全国发病率,死亡率和死亡率的大部分。
医疗费用。最近的研究结果表明,通过靶向治疗,
基本的衰老过程有几种这样的干预措施已经接近进入人类概念验证阶段
临床试验由于现在存在增加哺乳动物寿命和健康寿命的干预措施,
假设针对衰老基本机制的临床干预可以延缓,预防,
或将与年龄有关的疾病和残疾作为一个群体来治疗,而不是一次一个。为了加速测试
假设,我们提出了一个翻译老年科学网络(TGN)。计划始于4年前,
NIA R24资助涉及122名衰老生物学和临床老年病学研究人员。我们的目标是让这个
从致力于共同工作的中心小组开始,
共同的措施和协议,允许全网络的学习,从互补的,小规模的,
概念“用例”临床研究。目标1是建立一个TGN来开发、实施、测试和协调
方法和标准操作规程(SOP),用于药物的转化早期试验,
针对基本的衰老过程。TGN将支持开发、协调和基础设施
围绕独立资助的“用例”试验(每年2-3次),使用临床前或
临床数据已经存在,例如用于特发性肺纤维化的senolytics的多中心试验,
不同的药物,以减少衰老细胞的负担,减轻老年妇女的脆弱性,和二甲双胍的试验,
增强对流感疫苗的免疫反应。基于这些“用例”试验,我们将简化和
协调整个TGN的批准、招募、样本收集、SOP和分析程序。目标二是
选择、优化和验证待分析的基本老化过程的辅助措施,
所有试验都是为了建立参考分析能力。现有的细胞衰老检测设施将扩大
分析血液,其他体液,细胞和活检从试验跨越和超越TGN,作为一个
国家资源。将开发和优化新的检测方法。该设施将扩大到包括实验室
超越TGN,并结合关键的基本衰老机制的测定,包括mTOR活性,蛋白抑制,
自噬、线粒体功能和表观遗传学。目标3是提供统计和数据管理
支持选择有效的研究设计,提供样本量估计并支持TGN范围内的数据输入
平台,以促进跨研究比较。目标4是建立一个生物库和储存库网络,
从临床试验中提取样本,以便在开发新的辅助研究问题时进行未来分析
并且分析变得可用。一种用于向老龄化社区的基础生物学传播样本的系统,
将制定生物库方案和操作手册。针对基础老化的翻译代理
将这一进程转化为主要慢性病和与年龄有关的残疾的干预措施可能具有变革性。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
NIA Translational Geroscience Network: An infrastructure to facilitate geroscience-guided clinical trials.
NIA 转化老年科学网络:促进老年科学指导临床试验的基础设施。
- DOI:10.1111/jgs.18901
- 发表时间:2024
- 期刊:
- 影响因子:6.3
- 作者:Tchkonia,Tamara;Kritchevsky,StephenB;Kuchel,GeorgeA;Kirkland,JamesL
- 通讯作者:Kirkland,JamesL
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JAMES L. KIRKLAND其他文献
JAMES L. KIRKLAND的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JAMES L. KIRKLAND', 18)}}的其他基金
COVID-FIS: A PHASE 2 PLACEBO-CONTROLLED PILOT STUDY IN COVID-19 OF FISETIN TO ALLEVIATE DYSFUNCTION AND EXCESSIVE INFLAMMATORY RESPONSE IN OLDER ADULTS IN NURSING HOMES
COVID-FIS:针对 COVID-19 的 FISETIN 缓解疗养院老年人功能障碍和过度炎症反应的 2 期安慰剂对照试点研究
- 批准号:
10208138 - 财政年份:2020
- 资助金额:
$ 78.43万 - 项目类别:
Targeting Cellular Senescence to Extend Healthspan
靶向细胞衰老以延长健康寿命
- 批准号:
10349480 - 财政年份:2019
- 资助金额:
$ 78.43万 - 项目类别:
Targeting Cellular Senescence to Extend Healthspan
靶向细胞衰老以延长健康寿命
- 批准号:
10561620 - 财政年份:2019
- 资助金额:
$ 78.43万 - 项目类别:
Targeting Cellular Senescence to Extend Healthspan
靶向细胞衰老以延长健康寿命
- 批准号:
10117964 - 财政年份:2019
- 资助金额:
$ 78.43万 - 项目类别:
相似海外基金
Interplay between Aging and Tubulin Posttranslational Modifications
衰老与微管蛋白翻译后修饰之间的相互作用
- 批准号:
24K18114 - 财政年份:2024
- 资助金额:
$ 78.43万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
EMNANDI: Advanced Characterisation and Aging of Compostable Bioplastics for Automotive Applications
EMNANDI:汽车应用可堆肥生物塑料的高级表征和老化
- 批准号:
10089306 - 财政年份:2024
- 资助金额:
$ 78.43万 - 项目类别:
Collaborative R&D
The Canadian Brain Health and Cognitive Impairment in Aging Knowledge Mobilization Hub: Sharing Stories of Research
加拿大大脑健康和老龄化认知障碍知识动员中心:分享研究故事
- 批准号:
498288 - 财政年份:2024
- 资助金额:
$ 78.43万 - 项目类别:
Operating Grants
Baycrest Academy for Research and Education Summer Program in Aging (SPA): Strengthening research competencies, cultivating empathy, building interprofessional networks and skills, and fostering innovation among the next generation of healthcare workers t
Baycrest Academy for Research and Education Summer Program in Aging (SPA):加强研究能力,培养同理心,建立跨专业网络和技能,并促进下一代医疗保健工作者的创新
- 批准号:
498310 - 财政年份:2024
- 资助金额:
$ 78.43万 - 项目类别:
Operating Grants
関節リウマチ患者のSuccessful Agingに向けたフレイル予防対策の構築
类风湿性关节炎患者成功老龄化的衰弱预防措施的建立
- 批准号:
23K20339 - 财政年份:2024
- 资助金额:
$ 78.43万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Life course pathways in healthy aging and wellbeing
健康老龄化和福祉的生命历程路径
- 批准号:
2740736 - 财政年份:2024
- 资助金额:
$ 78.43万 - 项目类别:
Studentship
NSF PRFB FY 2023: Connecting physiological and cellular aging to individual quality in a long-lived free-living mammal.
NSF PRFB 2023 财年:将生理和细胞衰老与长寿自由生活哺乳动物的个体质量联系起来。
- 批准号:
2305890 - 财政年份:2024
- 资助金额:
$ 78.43万 - 项目类别:
Fellowship Award
I-Corps: Aging in Place with Artificial Intelligence-Powered Augmented Reality
I-Corps:利用人工智能驱动的增强现实实现原地老龄化
- 批准号:
2406592 - 财政年份:2024
- 资助金额:
$ 78.43万 - 项目类别:
Standard Grant
McGill-MOBILHUB: Mobilization Hub for Knowledge, Education, and Artificial Intelligence/Deep Learning on Brain Health and Cognitive Impairment in Aging.
McGill-MOBILHUB:脑健康和衰老认知障碍的知识、教育和人工智能/深度学习动员中心。
- 批准号:
498278 - 财政年份:2024
- 资助金额:
$ 78.43万 - 项目类别:
Operating Grants
Welfare Enhancing Fiscal and Monetary Policies for Aging Societies
促进老龄化社会福利的财政和货币政策
- 批准号:
24K04938 - 财政年份:2024
- 资助金额:
$ 78.43万 - 项目类别:
Grant-in-Aid for Scientific Research (C)